摘要
目的:观察吉西他滨和替吉奥联合方案对晚期乳腺癌的临床治疗效果。方法:选取我院31例对蒽环类和(或)紫杉类耐药的晚期乳腺癌患者作为研究对象,对所有对象采用吉西他滨(1 000 mg.m-2,静脉滴注0.5 h)和替吉奥(80 mg.m-2.d-1,分2次餐后0.5 h口服,连续口服1～14 d)联合方案进行治疗,每3周为1个治疗周期,至少治疗2个周期,观察所有对象的临床治疗效果及不良反应发生情况。结果:所有患者在接受吉西他滨和替吉奥联合方案进行治疗2个月后随访并评估其疗效,完全缓解(CR)2例,部分缓解(PR)8例,稳定(SD)13例,进展(PD)8例,有效率为32.26%,临床获益率为74.19%。不良反应以骨髓抑制和胃肠道反应为主,但均可耐受。结论:对蒽环类和(或)紫杉类耐药的晚期乳腺癌患者采用吉西他滨和替吉奥联合方案进行治疗,有较好的临床治疗效果,不良反应也较轻,值得临床推广使用。
Objective： To observe the curative effect of gemcitabine combined with S-1 on patients with advanced breast cancer.Methods： A total of 31 patients with advanced breast cancer were enrolled into this study.All the subjects were treated with gemcitabine（1 000 mg.m-2,iv 0.5 h） and S-1（80 mg.m-2.d-1,oral administration after meal,two times,d1-d14）.Three weeks was a cycle.Minimum 2 cycles were given.The following parameters of all the subjects were observed： clinical curative effect and adverse reactions.Results： The curative effect and adverse reactions could be evaluated in 31 patients with 2 of CR,8 of PR,13 of SD,8 of PD,the response rate and clinical benefit rate were 32.26% and 74.19%,respectively.The most common adverse reactions were hematological and digestive toxic reaction.Conclusion： Patients with anthracycline-and（or） taxanes-resistant advanced breast cancer who were treated with gemcitabine combined with S-1 have a better curative effect.And their adverse reactions were also small.So it is worthy of uses in clinical decisions.
出处
《现代医学》
2013年第6期407-409,共3页
Modern Medical Journal
